Mission Statement, Vision, & Core Values (2026) of Supriya Lifescience Limited.

Rooted in Mumbai since its founding in 1987, Supriya Lifescience Limited is a publicly listed generic pharmaceutical company that combines a focused portfolio of niche, high-value APIs and Finished Dosage Forms with a cGMP-compliant manufacturing hub in Lote-approved by regulators such as the US FDA, EDQM/EUGMP and Health Canada-and a global footprint that already spans over 86 countries, serving more than 1,500 customers with a committed team of over 400 employees; driving a remarkable 22% CAGR since 2019, the company's mission to lead targeted therapeutic categories is anchored in integrity, quality and commercially sustainable processes, its vision prioritizes innovation-backed, regulatory-compliant portfolio expansion and ambitious environmental targets like carbon neutrality by 2025 and water-use reduction via recycling, while core values of consistency, employee safety, ethical practice and social responsibility propel ongoing investments in R&D, quality assurance and community programs that invite deeper exploration of how Supriya translates numbers into patient-centric impact.

Supriya Lifescience Limited (SUPRIYA.NS) - Intro

• Founded: 1987 (Mumbai, India)
• Business model: API and FDF development, manufacturing, and commercialization
• Employees: >400
• Customers: >1,500 across 86+ countries
• Facilities: Primary API manufacturing at Lote, Maharashtra (cGMP)

• Develop and supply high-quality, cost-effective APIs and FDFs that address unmet needs in global therapeutics.
• Maintain compliance with global regulatory standards while scaling manufacturing capabilities.
• Create shareholder value through sustainable growth, innovation and operational excellence.

• To be a globally trusted supplier of niche and high-value pharmaceutical ingredients and finished formulations.
• To expand presence in regulated markets while driving margin-accretive product mix and R&D-led differentiation.
• To achieve measurable sustainability milestones (carbon neutrality and water-efficiency) while scaling exports.

• Quality & Compliance - adherence to cGMP and international regulatory standards (US FDA, EDQM, Health Canada).
• Integrity - ethical manufacturing, transparent reporting and responsible sourcing.
• Customer Centricity - reliable supply chain, technical support and long-term partnerships with 1,500+ customers.
• Innovation - focus on niche APIs, process optimization and cost-effective scale-up.
• Sustainability - committing to carbon neutrality by 2025 and 30% water-use reduction through recycling initiatives.

• Lote, Maharashtra facility: cGMP-compliant API manufacturing with multiple international approvals (US FDA, EDQM/EUGMP, Health Canada).
• Quality systems and documentation aligned for exports to 86+ countries, supporting a diversified revenue base.
• Emphasis on high-value therapeutic segments (anti-histamines, anti-allergics, vitamins, anesthetics, anti-asthmatics) to capture better margins.

• Target: Carbon neutrality by 2025, driven by energy efficiency, renewables and offset strategies.
• Water stewardship: Implementing recycling and reuse to reduce fresh water consumption by 30%.
• Ethical practices: Continued alignment with global compliance frameworks and supplier audits.

Supriya Lifescience Limited (SUPRIYA.NS) - Overview

• Customer-centric product development: focus on formulations and APIs aligned to prescriber and patient needs.
• Sustainability & consistency: embedding repeatable, scalable processes to ensure uninterrupted supply and predictable quality.
• Integrity & reliability: meeting quality standards and delivery timelines to retain long-term customer trust.
• Regulatory compliance & portfolio relevance: expanding product range in line with domestic and international regulatory frameworks.
• Innovation-driven manufacturing: adopting process improvements to reduce cost-of-goods and increase competitiveness in therapeutic niches.
• Adaptive culture: minimizing complexity, encouraging new ideas, and remaining responsive to market and regulatory change.

• Revenue scale: company operates in the mid-cap pharma space with reported annual revenues in the low thousands of crores INR range (single-digit billion INR band in recent fiscal years).
• Profitability focus: driving margin expansion through better mix (higher-margin formulations), manufacturing efficiency and backward integration of API intermediates.
• CapEx & R&D: targeted capex for capacity expansion and compliance upgrades, with R&D investment prioritized toward formulation development and process improvements (typical annual R&D spend mid-single-digit percentage of revenue).
• Market footprint: domestic leadership in select therapeutic categories with export presence; growth levered by regulatory approvals and new product introductions.

• Integrity - transparent reporting, ethical supply-chain practices and adherence to regulatory norms.
• Sincerity - dependable partner for customers, ensuring quality and timely fulfillment.
• Adaptability - simplified structures to enable faster decision-making and adoption of new opportunities.
• Innovation - continual process and product innovation to improve patient access and cost efficiency.

Supriya Lifescience Limited (SUPRIYA.NS) - Mission Statement

• Driving product innovation and lifecycle enhancement to meet evolving therapeutic needs.
• Establishing market leadership across targeted therapeutic segments with a focus on injectable and specialty APIs and formulations.
• Adopting sustainable manufacturing practices to minimize environmental footprint and support long-term value creation.
• Maintaining robust regulatory compliance across key markets to ensure patient safety and market access.

• Innovation-driven manufacturing: sustained investment in R&D, process development, and technology transfer to accelerate time-to-market.
• Quality and compliance: world-class quality systems and regulatory readiness for stringent markets (including EU, USFDA expectations as applicable).
• Sustainability commitments: aggressive targets for carbon and water reduction embedded into plant operations and supply chain.
• Portfolio expansion and market relevance: focused entry into high-growth therapeutic niches and generics with differentiated dossiers.
• Organizational adaptability: simplified structures, idea-driven culture, and rapid response to market dynamics.

• Carbon neutrality target: achieve carbon neutrality by 2025 across owned operations through renewable energy adoption, energy efficiency projects, and carbon offsets.
• Water stewardship: implement water recycling programs with the objective of reducing overall water usage by 30% versus baseline within the defined timeline.
• Waste reduction: focus on hazardous waste minimization, solvent recovery, and zero liquid discharge (ZLD) where feasible.

• Quality-First: uncompromising adherence to product quality, patient safety, and regulatory standards.
• Innovation: continuous improvement in chemistries, formulations, and manufacturing processes.
• Sustainability: integrating environmental responsibility into business decisions and operations.
• Integrity: transparent governance, ethical conduct, and accountable stakeholder engagement.
• Agility: reducing complexity, encouraging new ideas, and adapting quickly to market and regulatory shifts.

• Process intensification for cost-efficient API manufacture and yield improvements.
• Development of differentiated injectable and specialty formulations to target hospital and institutional markets.
• Regulatory lifecycle management to convert development assets into approved, market-ready products across geographies.

• Capacity expansion and technology upgrades to support scale-up of high-margin products.
• Quality systems aligned with international GMP and regulatory inspection readiness.
• Supply-chain resilience initiatives including dual sourcing and inventory optimization.

Supriya Lifescience Limited (SUPRIYA.NS) - Vision Statement

• Sustainability & Consistency - embedding long-term, resource-efficient practices across operations to ensure reliable supply and enduring stakeholder value.
• Integrity & Sincerity - retaining customer trust through uncompromising quality, ethical conduct, and adherence to delivery timelines.
• Innovation & Agility - simplifying complexity, fostering new ideas, and adapting rapidly to evolving market dynamics and regulatory landscapes.
• Quality Assurance & Safety - ensuring the highest standards from process to product and cultivating a safe, congenial workplace for employees.
• Environmental Responsibility - measuring, managing, and minimizing environmental impact via water conservation, waste management, and emissions control.
• Social Responsibility - driving sustainable growth by empowering underprivileged communities through education, healthcare, and rural development programs.

• Quality systems: GMP, ISO-aligned processes, routine external audits, and batch-release protocols to maintain zero-compromise quality.
• Environmental metrics: water-use audits, effluent treatment plants, and targets to lower specific water and energy consumption per kg of product.
• Innovation pipeline: continuous process optimization projects aimed at reducing cycle time and cost-per-unit while enhancing product portfolio flexibility.
• Social programs: regular community outreach in education, health camps, and rural upliftment initiatives focused on long-term empowerment.
• Stakeholder governance: transparent reporting, timely disclosures to investors, and adherence to corporate governance norms for persistent trust-building.

• Maintain and upgrade GMP-compliant manufacturing capacity to meet growing global demand while ensuring timely deliveries.
• Continuously reduce environmental footprint via measurable targets (water, energy, waste intensity) and published progress.
• Drive product and process innovation to lower complexity, enhance margins, and expand contract-manufacturing partnerships.
• Invest in employee safety, training, and well-being to sustain a high-performance, ethical workforce.